Home Cart Sign in  
Chemical Structure| 1173900-33-8 Chemical Structure| 1173900-33-8

Structure of AZD 6482
CAS No.: 1173900-33-8

Chemical Structure| 1173900-33-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD 6482 (KIN-193) exhibits potency and selectivity as a p110β inhibitor, with an IC50 of 0.69 nM.

Synonyms: KIN-193

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZD 6482

CAS No. :1173900-33-8
Formula : C22H24N4O4
M.W : 408.45
SMILES Code : O=C(O)C1=CC=CC=C1N[C@@H](C2=CC(C)=CN(C2=NC(N3CCOCC3)=C4)C4=O)C
Synonyms :
KIN-193
MDL No. :MFCD16659062
InChI Key :IRTDIKMSKMREGO-OAHLLOKOSA-N
Pubchem ID :44137675

Safety of AZD 6482

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of AZD 6482

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110β

    PI3Kβ, IC50:10 nM

  • p110α

    PI3Kα, IC50:870 nM

  • p110δ

    PI3Kδ, IC50:80 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
endometrial cancer cells 1 μM to 10 μM 72 hours to evaluate the effect of AZD 6482 on PTEN-mutant endometrial cancer cells, results showed minimal impact on cell viability with AZD 6482 alone PMC3700760
U87 0.625-40 µM 48 h AZD6482 significantly inhibited the proliferation of U87 cells and induced apoptosis and cell cycle arrest. PMC6278584
U118 0.625-40 µM 48 h AZD6482 significantly inhibited the proliferation of U118 cells and induced apoptosis and cell cycle arrest. PMC6278584
bone marrow cells 1 μM 7 days KIN193 significantly reduced the formation of myeloid colonies from both bone marrow and spleen in Pten-deficient mice, indicating that p110β inhibition has a significant impact on myeloid cell expansion. PMC4598950
BM cells 1 μM 2 hours Inhibition of p110 b led to a significant reduction of p-Akt in BM cells from PTEN-deficient mice. PMC4598950
spleen cells 1 μM 2 hours Inhibition of p110 b led to a significant reduction of p-Akt in spleen cells from PTEN-deficient mice. PMC4598950

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice Pten-deficient mouse model intraperitoneal injection 1, 10, or 30 mg/kg Once daily for 14 days KIN193 significantly prolonged the survival of Pten-deficient mice and reduced spleen weight and myeloid cell infiltration, indicating that p110β inhibition has a significant therapeutic effect on myeloid leukemia. PMC4598950
Mice Nude mice Intraperitoneal injection 10 mg/kg Once daily for 14 days Evaluate the pharmacokinetic and pharmacodynamic properties of KIN-193 in vivo PMC3384541
mice Pten-deficient mice intraperitoneal injection from day 0 after T-cell transfer until sacrifice Inhibition of p110 b significantly prolonged the survival of Pten-deficient mice and reduced spleen weight and cellularity. PMC4598950

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00853450 Antiplatelet Effect Phase 1 Completed - Sweden ... More >> Research Site Lund, Sweden Less <<
NCT00688714 Antiplatelet Effect Phase 1 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.45mL

0.49mL

0.24mL

12.24mL

2.45mL

1.22mL

24.48mL

4.90mL

2.45mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories